Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

3(37.5%)

8Total

Phase 1(5)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07187531Phase 2Recruiting

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Role: lead

NCT04850898Phase 2Completed

Study of SAB-176 in Healthy Adult Participants

Role: lead

NCT04471038Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Role: lead

NCT06435936Phase 1Active Not Recruiting

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

Role: lead

NCT04518410Phase 2Completed

ACTIV-2: A Study for Outpatients With COVID-19

Role: collaborator

NCT04468958Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

Role: lead

NCT04469179Phase 1Unknown

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

Role: lead

NCT02788188Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

Role: collaborator

All 8 trials loaded